|
COMMERCE BUSINESS DAILY ISSUE OF MAY 17,2000 PSA#2602National Cancer Institute, Research Contracts Branch, PSAS, 6120
Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227 66 -- WAVE NUCLEIC ACID FRAGMENT ANALYSIS SYSTEM SOL RFQ-NCI-00121 DUE
060200 POC Cynthia Brown, Purchasing Agent, 301-402-4509, Todd Cole,
Contracting Officer The National Institutes of Health, National Cancer
Institute (NCI), Laboratory of Population Genetics plans to procure a
Wave Nucleic Acid Fragment Analysis System from Transgenomic, Inc.,
5600 S 42nd Street, Omaha, NE 68107. The major focus of the Laboratory
of Population Genetics is the identification of DNA sequence
variations in human populations that may predispose individuals to
diseases like cancer. The Laboratory recently began using a WAVE
Nucleic Acid Fragment Analysis System to replace single-strand
conformational polymorphism analysis, which has approximately 70%
sensitivity for the analysis of the BRCA1 and BRCA2 genes. The
experimental conditions for analysis have been optimized for the WAVE
Nucleic Acid Fragment Analysis System and appears to have over 95"
sensitivity in detecting mutations. The WAVE Neucleic Acid Fragment
Analysis System is the only "complete" system having the necessary
sensitivity that has a liquid chromatography apparatus, auto-sampler,
oven, chromatography column, and software. The most important aspect,
and other unique feature of the system, is the DNA Sep chromatography
cartridge HPLC column with a propreitary matrix. The cartridge is
formatted and optimized for the detection of sequence variation in
double-stranded DNA on the system. The Transgenomic system includes a
computer-controlled column oven with a range of 35-80 degree "C" and a
precision of 0.1 degree "C" along with heating and cooling devices for
temperature control of the separation buffers since temperature is an
important parameter in the research. The Autosampler is formatted for
96-well trays, can be injected between 1 and 100 il of sample,
temperature controlled from 4-60 degrees "C". The overall system is
computer controlled and contains proprietary software to aid in using
the system and analyzing the output data. In order to increase the
number of samples we may analyze without introducing any additional
experimental variables, such as different instruments with different
characteristics, we planto purchase an additional WAVE Nucleic Acid
Fragment Analysis System. Transgenomic Inc., is the only source known
to the NCI Researcher that provides a "complete" instrument with high
sensitivity that would not require the introduction of additional
experimental variability into our analyses and has the
sensitivity/features noted above. This is not a request for competitive
quotation. However, if any interested party believes it can meet the
above requirements, it may submit a statement of capabilities. The
capability statement and any other furnished information must be in
writing and must contain material in sufficient detail to allow NCI to
determine if the party can fully meet the requirements. Capability
statements must be received in the contracting office by 2:00 pm, EST
(local Washington time) on June 2, 2000. If you have any questions,
please contact Cynthia Brown, Purchasing Agent, on (301) 402-4509. A
determination by the Goverment not to compete this proposed requirement
based on responses to this notice is solely within the discretion of
the Government. Information received shall be considered soley for the
purpose of determining whether to conduct a competitive procurement.
No collect calls of faxes will be accepted. Please refer to
solicitation number RFQ-NCI-00121. Posted 05/15/00 (W-SN454756).
(0136) Loren Data Corp. http://www.ld.com (SYN# 0252 20000517\66-0002.SOL)
66 - Instruments and Laboratory Equipment Index Page
|
|